Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 3, Pages 482
Publisher
MDPI AG
Online
2022-01-19
DOI
10.3390/cancers14030482
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations
- (2021) Rachel M. Layman et al. CANCER JOURNAL
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
- (2021) Remy Thomas et al. Frontiers in Oncology
- Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
- (2021) Hesham Elghazaly et al. Cancers
- Triple-negative breast cancer: understanding Wnt signaling in drug resistance
- (2021) Parnaz Merikhian et al. Cancer Cell International
- Immunotherapy Treatment for Triple Negative Breast Cancer
- (2021) Elizabeth R. Berger et al. Pharmaceuticals
- Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
- (2021) Won-Ji Ryu et al. Pharmaceuticals
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
- (2020) Olivier Zajac et al. Cells
- Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
- (2020) Katarzyna Pogoda et al. Journal of Oncology
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
- (2020) Abderrahim El Guerrab et al. Scientific Reports
- Tissue resident macrophages promote extracellular matrix homeostasis in the mammary gland stroma of nulliparous mice
- (2020) Ying Wang et al. eLife
- Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
- (2020) Anna Diana et al. Cancers
- Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
- (2020) Soong June Bae et al. Scientific Reports
- Gas6 expression is reduced in advanced breast cancers
- (2020) Ayman M. Ibrahim et al. npj Precision Oncology
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- TGF-β suppresses type 2 immunity to cancer
- (2020) Ming Liu et al. NATURE
- Diverse Macrophage Populations Contribute to the Inflammatory Microenvironment in Premalignant Lesions During Localized Invasion
- (2020) Ayman M. Ibrahim et al. Frontiers in Oncology
- Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
- (2020) Xiufang Xu et al. Molecular Cancer
- New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
- (2020) Ye Han et al. Frontiers in Oncology
- Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer
- (2019) Dilan A. Patel et al. BREAST CANCER RESEARCH AND TREATMENT
- Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
- (2019) Nuramalina H. Mumin et al. BMC CANCER
- Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor
- (2019) Kamal Ahmed et al. CANCER LETTERS
- β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue
- (2019) Satheesh Kumar Sengodan et al. CARCINOGENESIS
- Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly
- (2019) Pia Giovannelli et al. Scientific Reports
- Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis
- (2019) Yunhai Li et al. Aging-US
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
- (2019) Ik Sun Kim et al. NATURE CELL BIOLOGY
- Myeloid-Derived Suppressor Cells Promote Metastasis in Breast Cancer After the Stress of Operative Removal of the Primary Cancer
- (2019) Xuelei Ma et al. Frontiers in Oncology
- Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
- (2019) Jessa Gilda P. Pandy et al. BMC CANCER
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
- (2019) Hamdy A. Azim et al. Breast Journal
- TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer
- (2019) Brian D. Lehmann et al. CLINICAL CANCER RESEARCH
- WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
- (2019) Elena Martin-Orozco et al. Frontiers in Immunology
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
- (2018) Nithya Krishnamurthy et al. CANCER TREATMENT REVIEWS
- Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.
- (2018) Murray Yule et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
- (2018) Elisa Peranzoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
- (2018) Christiana Neophytou et al. Frontiers in Oncology
- Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
- (2018) Si-Qi Qiu et al. CANCER TREATMENT REVIEWS
- Precision medicine based on tumorigenic signaling pathways for triple‑negative breast cancer (Review)
- (2018) Nan Wu et al. Oncology Letters
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
- (2018) Haixia Chen et al. Frontiers in Pharmacology
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
- (2018) Fouzia Guestini et al. BREAST CANCER RESEARCH AND TREATMENT
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stromal Gas6 promotes the progression of premalignant mammary cells
- (2018) Angelica M. Gomes et al. ONCOGENE
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Hsp90 Inhibitors on Patient Derived Triple Negative Breast Cancer (TNBC) Cells: BRCA1 as a Therapeutic Target for TNBC
- (2017) Shrikant Anant et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
- (2017) Saima Hassan et al. MOLECULAR CANCER THERAPEUTICS
- Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
- (2017) Amanda E D Van Swearingen et al. NEURO-ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells
- (2016) Yan Zhou et al. BMC CANCER
- A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
- (2016) Alejandra Bruna et al. CELL
- Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
- (2016) Wilhem Leconet et al. CLINICAL CANCER RESEARCH
- Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage
- (2016) Valeria Fernandez Vallone et al. DEVELOPMENT
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
- (2016) Yaqiong Tian et al. ONCOLOGY RESEARCH
- Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
- (2016) Junjun Liu et al. TUMOR BIOLOGY
- Luminal B breast cancer: patterns of recurrence and clinical outcome
- (2016) Zhi-hua Li et al. Oncotarget
- Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis
- (2015) A. Koval et al. BIOCHEMICAL JOURNAL
- Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients
- (2015) Mirco Pistelli et al. BMC CANCER
- PARP inhibitors in the management of breast cancer: current data and future prospects
- (2015) Luca Livraghi et al. BMC Medicine
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer
- (2015) Lyndsay V. Rhodes et al. Oncotarget
- Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators
- (2014) Lyndsay V. Rhodes et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy
- (2014) Minoru Miyashita et al. BREAST CANCER RESEARCH AND TREATMENT
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
- (2014) Komal Jhaveri et al. Clinical Breast Cancer
- High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis
- (2014) Zhong-Yu Yuan et al. OncoTargets and Therapy
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
- (2013) H. R. Kim et al. ANNALS OF ONCOLOGY
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
- (2013) Julie C. Friedland et al. INVESTIGATIONAL NEW DRUGS
- Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner
- (2013) Nandini Dey et al. PLoS One
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
- (2012) Anneleen Daemen et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer, side population cells and ABCG2 expression
- (2012) K.M. Britton et al. CANCER LETTERS
- High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients
- (2012) C. Bartholomeusz et al. ONCOLOGIST
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
- (2011) H E Lee et al. BRITISH JOURNAL OF CANCER
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade
- (2011) Kristi Baker et al. HISTOPATHOLOGY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- Triple-negative breast cancer: disease entity or title of convenience?
- (2010) Lisa Carey et al. Nature Reviews Clinical Oncology
- Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
- (2009) Carey K. Anders et al. Clinical Breast Cancer
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now